A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)

A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)

Objective: InO is a CD22-directed antibody-drug conjugate indicated for treatment of relapsed/refractory (R/R) ALL. InO has been associated with hepatotoxicity and hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), particularly post-HSCT. Registry data from the Center for Inte...

Full description

Bibliographic Details
Main Authors: David MARKS, Marcos DE LIMA, Partow KEBRIAEI, Francesco LANZA, Christina CHO, Sergio GIRALT, Gizelle POPRADI, Michael HEMMER, Wael SABER, Xin ZHANG, Richa SHAH, Verna WELCH, Erik VANDENDRIES, Matthias STELLJES
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137921011603

Internet

http://www.sciencedirect.com/science/article/pii/S2531137921011603

Similar Items